For a 15-year-old female with moderate depressive symptoms (PHQ-9A score 14), moderate anxiety symptoms (GAD-7 score 10), functional impairment, and passive suicidal ideation without a plan, what is the recommended first-line selective serotonin reuptake inhibitor (including FDA-approved age indication, starting dose, titration schedule, adequate trial duration, and monitoring), and what alternative should be used if the first SSRI is ineffective or not tolerated, according to American Academy of Pediatrics (AAP), American Academy of Child and Adolescent Psychiatry (AACAP), and FDA labeling?

First-Line SSRI Recommendation for 15-Year-Old Female with Moderate Depression, Anxiety, and Passive Suicidal Ideation

Fluoxetine is the recommended first-line SSRI for this 15-year-old patient, as it is the only FDA-approved antidepressant for adolescent depression (ages 8 years and older) and has the strongest evidence base for both efficacy and safety in this age group. 1, 2, 3

FDA-Approved Indications by Age

• Fluoxetine: FDA-approved for major depressive disorder in children/adolescents aged 8 years and older 2
• Escitalopram: FDA-approved for major depressive disorder in adolescents aged 12 years and older 3, 4

While escitalopram is also FDA-approved for this patient's age, fluoxetine has superior evidence for efficacy in adolescent depression and is considered the first choice when antidepressant treatment is indicated 1, 5.

Dosing Protocol for Fluoxetine

Starting Dose

• 10 mg once daily 3

Titration Schedule

• Increase by 10-20 mg increments 3
• Use slow up-titration to avoid exceeding optimal dose and minimize behavioral activation/agitation 6
• Most adverse effects emerge within the first few weeks, supporting gradual dose increases 6

Effective Dose Range

• 20 mg daily (typical effective dose) 3

Maximum Dose

• 60 mg daily 3

Adequate Trial Duration

• Clinically significant improvement by week 6
• Maximal improvement by week 12 or later 6
• Continue treatment for 9-12 months after symptom improvement before considering discontinuation 4

Critical Monitoring Requirements

Suicidality Monitoring (Black Box Warning)

Given this patient's passive suicidal ideation, close monitoring for suicidality is mandatory, especially in the first months of treatment and following dosage adjustments 6. The FDA black box warning applies to all patients through age 24 years 6.

Monitoring schedule:

• Initial contact (in-person or telephone) within 1 week of starting medication 3
• Weekly contact for the first month (can be telephone-based) 3
• Then biweekly for the second month
• Then monthly thereafter during the acute phase

Specific Adverse Events to Monitor

Early treatment phase (first 4 weeks):

• Behavioral activation/agitation: motor restlessness, insomnia, impulsiveness, talkativeness, disinhibited behavior, aggression 6
• Suicidal ideation or behavior: pooled risk difference of 0.7% (NNH = 143 vs. NNT = 3 for response) 6
• Akathisia: specifically linked to emergence of suicidal ideation in some cases 1

Common adverse effects:

• Gastrointestinal: nausea, diarrhea, heartburn
• CNS: headache, insomnia, somnolence, dizziness
• Other: changes in appetite, weight changes, tremor 6

Serious but rare adverse effects:

• Mania/hypomania (may appear later than behavioral activation)
• Serotonin syndrome (if combined with other serotonergic agents)
• Seizures
• Abnormal bleeding 6

Patient and Family Education

Before starting treatment, educate about:

• Expected timeline for improvement (6-12 weeks for full effect)
• Potential for behavioral activation in early treatment
• Importance of reporting increased agitation, restlessness, or worsening suicidal thoughts immediately
• Need for third-party supervision of medication administration given suicidal ideation 1

Recommended Alternative if Fluoxetine is Ineffective or Not Tolerated

Escitalopram is the recommended second-line SSRI if fluoxetine is ineffective after an adequate trial (12 weeks at therapeutic dose) or not tolerated 3, 4.

Escitalopram Dosing

• Starting dose: 10 mg once daily
• Increments: 5 mg
• Effective dose: 10 mg daily
• Maximum dose: 20 mg daily 3

Rationale for Escitalopram as Alternative

• FDA-approved for adolescents aged 12 years and older
• Generally well-tolerated with similar adverse effect profile to fluoxetine
• Once-daily dosing with sufficient half-life 6

Other Considerations if Both First-Line Options Fail

• Sertraline (starting 25 mg, effective dose 50 mg, maximum 200 mg) may require twice-daily dosing at low doses 6, 3
• Consider combination therapy with cognitive behavioral therapy (CBT), which shows superior outcomes and lower suicidality rates compared to SSRI monotherapy 7, 5
• Reassess diagnosis and consider comorbid conditions

Critical Safety Considerations

Contraindications

• Monoamine oxidase inhibitors (MAOIs) - absolute contraindication for all SSRIs 3

Discontinuation

• Always taper slowly when discontinuing to avoid withdrawal effects 3
• Do not abruptly stop medication

Overdose Risk

While SSRIs have lower lethality in overdose compared to tricyclic antidepressants, deaths have been reported with very large ingestions 6, 1. Given this patient's suicidal ideation, ensure third-party supervision of medication administration 1.

When to Avoid Starting at Higher Doses

Never start at higher than recommended starting doses - deliberate self-harm and suicide risk are more likely with higher initial doses 3. This is particularly important given this patient's passive suicidal ideation.

Integration with Psychotherapy

Strongly recommend concurrent cognitive behavioral therapy (CBT) - combination therapy demonstrates better outcomes and lower rates of treatment-emergent suicidality compared to SSRI monotherapy 7, 5. The combination of fluoxetine plus CBT was superior to either treatment alone in the landmark TADS study 5.